Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 October 2009Website:
http://www.omeros.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 20:04:52 GMTDividend
Analysts recommendations
Institutional Ownership
OMER Latest News
Omeros Corporation's Q1 2024 Earnings Conference Call will begin at 4:30 PM ET on May 15, 2024. The call will feature company representatives including Jennifer Williams, Greg Demopulos, Mike Jacobsen, Andreas Grauer, Steve Whitaker, Nadia Dac, and Catherine Melfi. Participants on the call include Steve Brozak and Olivia Brayer from WBB Securities and Cantor Fitzgerald, respectively. All participants are currently in listen-only mode.
Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript
Omeros Corporation focuses on small-molecule and antibody drugs for common disorders and rare diseases. The company has prioritized the resubmission of its BLA for Narsoplimab for TA-TMA treatment and is advancing Phase-3 clinical trials for MASP-3 inhibitor OMS906. Narsoplimab holds promise for treating TA-TMA, COVID-19, and Lupus Nephritis but faces competition in the latter two conditions.
Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of the late-stage study.
Omeros Corporation's share price has seen significant run-ups in recent months despite disappointing first quarter results in 2023 and the company's lack of profitability. The company was awarded $6.69 million from the National Institute on Drug Abuse for its program OMS527, which focused on the treatment of cocaine use disorder. However, it also has $344 million in long-term debts. Omeros' future heavily relies on FDA approval of its drug candidates, particularly Narsoplimab, and faces intense competition in the biopharmaceutical sector.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 23, 2023, starting at 10:00 a.m. Pacific Time. A live webcast of the Annual Meeting of Shareholders can be accessed through www.virtualshareholdermeeting.com/OMER2023. A general corporate overview and question and answer session is expected to follow the business portion of the annual meeting. A.
The company's lead therapy, Narsoplimab, has not yet been approved. As of the first quarter, Omeros had $371.4 million in cash.
Omeros Corporation (NASDAQ:OMER ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and CEO Mike Jacobsen - Chief Accounting Officer Nadia Dac - Chief Commercial Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Medical Officer Conference Call Participants Steve Brozak - WBB Securities Greg Harrison - Bank of America Elliott Bosco - UBS Brandon Folkes - Cantor Fitzgerald Operator Good afternoon, and welcome to today's earnings call from Omeros Corporation. At this time, all participants are in a listen-only mode.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conference call via phone.
What type of business is Omeros?
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
What sector is Omeros in?
Omeros is in the Healthcare sector
What industry is Omeros in?
Omeros is in the Biotechnology industry
What country is Omeros from?
Omeros is headquartered in United States
When did Omeros go public?
Omeros initial public offering (IPO) was on 08 October 2009
What is Omeros website?
https://www.omeros.com
Is Omeros in the S&P 500?
No, Omeros is not included in the S&P 500 index
Is Omeros in the NASDAQ 100?
No, Omeros is not included in the NASDAQ 100 index
Is Omeros in the Dow Jones?
No, Omeros is not included in the Dow Jones index
When does Omeros report earnings?
The next expected earnings date for Omeros is 09 August 2024